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Abstract 
Objective: Lysyl oxidase (LOX) dependent cross-linking is deficient in diabetic 
bone, contributing to osteopenia. Here we Investigate regulation of lysyl oxidase by 
Wnt3a and TNF-a in a mesenchymal stem cell line as a model for a novel mechanism of 
diabetic osteopenia. 
Methods: Wnt3a-treated C3Hl 0Tl/2 cells were treated with or without of TNF-a. 
Lysyl oxidase expression ( qPCR) and mRNA stability were measured. A comprehensive 
PCR-based microarray screen (Qiagen/SA Biosciences) was next performed to_ identify 
miRNAs which regulate LOX mRNA stability in response to TNF-a. The functionality of 
identified miRNA was independently determined by the use of miRNA mimics. 
Results: Wnt3a up-regulated LOX up to 3.2-fold by treating C3H10Tl/2 cells 
with Wnt3a compared to controls. TNF-a (20 ng/ml) blocked Wnt3a up-regulation of 
LOX. TNF-a decreased the stability of LOX mRNA determined in the presence of a 
transcription inhibitor in control- and Wnt3a plus TNF-a-treated cells. A micro (miR) 
array screen performed on RNA isolated from Wnt3a plus TNF-a treated and control 
cells identified miR203 as being up-regulated 13-fold by TNF-a. Independent analyses 
IV 
employing a miR203 mimic demonstrated the functionality of TNF-a induced miR203 to 
target LOX mRNA. 
Conclusion: TNF-a down-regulates LOX in Wnt3a treated C3H10Tl/2 cells by 
post-transcriptional control mediated by miR203. This is the first study to identify any 
miR which targets lysyl oxidase. Data suggest that TNF-a may contribute to diabetic 
osteopenia by targeting LOX in mesenchymal stem cells, thereby resulting in abnormally 
low mesenchymal cell differentiation, collagen cross-linking and osteopenia observed in 
diabetic bone disease. 
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Introduction and Literature Review 
Diabetic bone disease 
According to the WHO (World Health Organization), more than 16 million people 
are affected by diabetes mellitus and this has become a major public health problem. 
Diabetic bone disease is a complication of diabetes, which consists of weak bones, low 
bone turnover, osteopenia, and low bone density. Osteopenia is a common bone disease 
associated with reduced bone mineral density (1, 2). The pathophysiological mechanisms 
of bone loss with diabetes include a reduction in osteoblast activity, ( osteoid formation 
and mineral apposition rate), not highly enhanced osteoclast activity, and/or the deficit of 
insulin's anabolic action (3). 
Some known complications of diabetes include atherosclerosis ( 4 ), renal disease 
(5), blindness (6), periodontal diseases (7, 8), and bone abnormalities (9-13). A major 
cause of these complications is the presence of elevated levels of advanced glycation end 
products (AGE) that result from non-enzymatic reactions of glucose and oxidized lipids 
with proteins (14, 15). More recent studies showed that bone formation is decreased in 
diabetes, but is not accompanied by decreased bone density (16, 17), which indicated that 
even without a decrease in bone density, bone quality is abnormally poor. This poor bone 
quality is related to changes in collagen structure including decreased lysyl oxidase-
dependent cross-linking and increased non-enzymatic glycation, such as AGEs (17). 
Tumor Necrosis Factor alpha (TNF-a) 
TNF-a was shown to be a major cytokine expressed m the diabetic hyper-
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inflammatory response to injury in diabetes (18), and TNF-a contributes to increased 
fibroblast apoptosis (19). TNF-a is mainly released by macrophages and monocytes 
(20), and by many other cell types including fibroblasts (21 ), keratinocytes (22), 
endothelial cells (23), and lymphocytes (24, 25). 
TNF-a has multiple properties and can modulate the expression of many genes. 
TNF-a can stimulate the acute phase response (26) and catabolism in general (27, 28). 
TNF -a stimulates the expression of many growth factors, such as nerve growth factor 
(29), angiogenic growth factors 1 and 2 (30). TNF-a up-regulates IL-2 (31), vascular 
endothelial growth factor receptor-2 and its co-receptor neuropilin-1 (32) and down-
regulates the activity of thyroid transcription factor 1 and Pax-8 (33). 
TNF-a inhibits osteoblast differentiation (34) by down regulating core binding 
factor alpha 1 (35) and osterix (36). It also suppresses alkaline 'phosphatase activity and 
matrix deposition (37-39) and inhibits collagen incorporation (37, 40). Lysyl oxidase is 
an important enzyme in collagen crosslinking. However, the effect of TNF-a on lysyl 
oxidase in the context of diabetes has not been specifically investigated. 
TNF a induced hyper-inflammatory response in diabetes 
TNFa might exert its effect as part of a hyper-inflammatory response, leading to 
tissue injury in diabetes patients through different mechanisms and unrelated independent 
pathways , many of which are still unclear. 
Pro-inflammatory cytokines such as IL 1 ~, TNF-a and interferon-y cause 
activation of the inducible nitric oxide synthase pathway in bone and the elaborated nitric 
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oxide potentiates bone loss ( 41 ). Elevated circulating TNF a levels in diabetes patients 
show direct correlation with vascular induced nitric oxide synthase expression, giving a 
possible link between inflammation and reduced bone mass (42, 43). High levels of 
nitric oxide result in impaired ossification via oxidative stress and autophagic osteoblast 
death ( 44 ). Oppositely, the production of AG Es may reduce bioavailability of nitric 
oxide in diabetes ( 45), and pharmacological nitric oxide donors increase bone mass ( 46), 
indicating the mechanisms through nitric oxide mediated osteoblast apoptosis are not 
fully understood yet. 
Another study in the MC3T3-El cell line indicated a totally different way leading 
to osteoblast apoptosis. TNFa induces liberation of arachidonate from diacylglycerol and 
increases prostaglandin synthesis, which induces apoptosis in various cell types and 
provokes cell death in mouse osteoblastic cell cultures ( 4 7). Furthermore , TNF-a appears 
to enhance injury, as shown by the fact that the injection of neutralizing TNF-a antibody 
into intracerebroventricular and brain cortex, respectively, significantly reduces 
experimental ischemic and traumatic injury ( 48, 49). 
Lysyl oxidase (LOX) 
Type I collagen makes up 90% of the organic matrix in bone (50). It is first 
translated from mRNA to form prepro-polypeptide chains on the rough endoplasmic 
reticulum. In the lumen of the endoplasmic reticulum, modifications are made and three 
pro-chains are assembled in a triple helix to form pro-collagen (51, 52). Next, the 
maturing pro-collagen is transported from the endoplasmic reticulum to the Golgi 
apparatus and ultimately secreted. These pro-collagen molecules are subsequently 
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cleaved by specific procollagen peptidases and packed into fibrils (53). Intra- and inter.:. 
molecular crosslinks are initiated and reinforced by lysyl oxidase (54). Once the collagen 
molecules are fully cross-linked the fibrils become insoluble matrix. 
Osteoblast differentiation is an interactive process of interaction between the 
developing cells and the extracellular matrix. LOX is a critical extracellular enzyme in 
the biosynthesis of normal collagen, because it catalyzes the final enzymatic reaction 
needed for producing lysine-derived collagen cross-links. It is increasingly apparent 
from recent human and animal studies that osteopenic bone due to diabetes ( 1 7), 
osteoporosis (55-57), and aging (58, 59) all contain ,. higher levels of non-enzymatic 
AGE cross-links , and lower levels of LOX dependent cross-links that accompany poor 
quality. 
LOX deficiency results in abnormal extracellular matrixformation, especially bone 
Type I collagen is the primary constituent of extracellular bone matrix and a 
crucial determinant for mechanical properties of bone tissue (60, 61). Post-translational 
collagen modifications lead to the formation of a mature functional matrix , which is 
essential for subsequent matrix mineralization (62-65). Lysyl oxidase initiates cross-
linking of collagen and elastin (62, 66). Diminished LOX enzyme activity results in an 
increased risk of bone deformities and fractures ( 67, 68), and altered collagen fibril 
formation and osteoblast differentiation (69). Extracellular post-translational 
modifications of fibrillar type I-III collagens by LOX are crucial for collagen cross-
linkage and for the accumulation of a functional collagen matrix in bone tissue ( 62, 66, 
70). 
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A more recent study showed that besides normal morphology of calcified 
structures, significant changes in collagen fibril formation as well as altered osteoblast 
differentiation were found in LOX knockout mice compared to wild type mice (69). The 
same group also showed that in osteoblastic cells (MC3T3-El) , LOX seems to be 
specifically regulated in the course of osteoblast cell differentiation and that this 
regulation is required for normal collagen deposition (71 ). 
A lack of LOX gene expression leads to perinatal lethality and this limitation made LOX 
knockout mice develop to term but die soon thereafter just before or at birth (72, 73). 
Furthermore , due to defective collagen and elastin cross-linkage , they suffer from severe 
cardiovascular and pulmonary defects (72-74). 
Advanced Glycation End Products (AGEs) 
AGEs are heterogeneous in structure, and its reactions result in non-enzymatic 
cross-linking of proteins . They occur at elevated levels in hyperlipidemia , secondary 
amyloidosis , Alzheimer 's disease, uremia and even normal aging (75-78). 
AGEs are formed by exposing proteins to oxidized lipids or reducing sugars 
which results in non-enzymatic glycation. AGEs formation and protein crosslinking 
induce the structural and functional changes of proteins , lipids and nucleic acids (79-81 ). 
AGEs alter not only the physicochemical properties of the affected molecules, but also 
cellular signaling and gene expression (82). 
AGEs are thought to act via their receptor, RAGE (receptor of advanced 
glycation end products) , to play a major role in diabetic complications in some tissues 
(83-85). RAGE is expressed in multiple tissues and cells including C3HIOT½cells (65, 
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86). The AGE/RAGE interaction activates a series of intracellular signaling pathways 
resulting in up-regulation of several kinds of cell adhesion molecules and cytokines 
including tumor necrosis factor-a (lNF-a) (13, 87). The presence of such interactions in 
bone may contribute to the tissue resorptive phenotype present in periodontal disease and 
diabetic osteopenia (88, 89). 
Role of AGE 
AGE can activate a number of receptors. The receptor known as receptor for 
advanced glycation end products (RAGE) is unique in that its· biological activity is 
associated with inflammation and a tissue resorptive phenotype, whereas other AGE 
receptors confer a fibrotic outcome, such as increased extracellular matrix production and 
fibrosis (90). Large AGE proteins unable to enter the Bowman's capsule are capable of 
binding to receptors on endothelial and mesangial cells and to the mesangial matrix (91) 
RAGE ligand inhibits bone healing in non-diabetic mice, mimicking the effect of diabetes 
itself, strongly implicating the AGE/RAGE pathway in diabetic osteopenia (89). 
Consistent with the findings, other studies also show that animals deficient in RAGE 
(RAGE knockout mice) have increased bone mineral density, increased bone strength, 
decreased osteoclast formation, and decreased levels of serum IL-6 (92, 93). A later 
study showed that AGEs induce apoptosis in osteoblasts by a RAGE dependent 
mechanism as demonstrated in experiments utilizing RAGE neutralizing antibodies (19, 
94). In addition to stimulating apoptosis , AGEs inhibit osteoblast differentiation (95). 
AGEs are accumulated in diabetes (96, 97), and provoke inflammation through 
up-regulation of lNFa (98, 99) in monocytes and macrophages. AGEs induce apoptosis 
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and senescence of chondrocytes (100, 101 ), as well as induce apoptosis in primary 
cultures of human or neonatal rat osteoblastic cells or MC3T3-El cells in vitro (94). 
Production of AGEs in diabetes, therefore, may be one possible thread linking insulin 
deficiency, TNFa up"".regulation and chondrocyte apoptosis (102). 
Wnt signaling pathway 
The W nt signaling pathway is a network of proteins best known for their roles in 
embryogenesis and cancer. It is also involved in normal physiological processes in adult 
animals (103). The Wnt proteins are a group of secreted lipid-modified signaling 
proteins of 350-400 amino acids in length (104). These proteins activate various 
pathways in the cell that can be roughly categorized into the canonical and noncanonical 
Wnt pathways (105). Through these signaling pathways, Wnt proteins play a variety of 
important roles in embryonic development, cell differentiation, and cell polarity 
generation (106). 
Among the different Wnt pathways, the canonical pathway is involved in 
osteoblast proliferation and differentiation (107). Wnt first binds to frizzled family 
protein receptors and initiates the inhibition of glycogen synthase kinase. Wnt signaling 
will result in the accumulation of ~-catenin in the osteoblast nucleus and interacts with 
transcription factors, which will eventually stimulate transcription of genes that inhibit 
apoptosis, stimulate proliferation, and early phases of osteoblast differentiation and 
extracellular matrix synthesis ( 108). 
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Wnt induces osteoblast differentiation and extracellular matrix formation 
Transient activation of Wnt/~-catenin signaling in mesenchymal stem cells 
(MSCs) in vitro suppresses transcription of adipogenic transcription factor peroxisome 
proliferator-activated receptor-y (PPAR-y) and induces expression of bone lineage genes 
such as Dlx5 and Osterix (109). Conversely, PPAR-y inhibits osteocalcin (OCN) 
expression by repressing both the expression and the trans-activation ability of Runx2 
(110), which is a key for osteoblast differentiation. Interestingly, the Runx2 gene 
promoter contains a Wnt-responsive T cell-specific transcription factors (TCFs) 
regulatory element, and both ~-catenin and TCP 1 are recruited to the Runx2 locus ( 111 ). 
Another study showed that Wntl and Wntl0b prevented adipogenesis of preadipocyte 
cells (112). Moreover, some Wnts (Wntl, Wnt2, and Wnt3a, but not Wnt4 or Wnt5) 
induced alkaline phosphatase (ALP) activity, an early event during osteoblast 
differentiation, in C2C12, C3H10T½, and ST2 cell lines (113, 114). Overall, these 
studies demonstrate that Wnts stimulate osteoblast precursor growth and some early 
events in osteoblast differentiation. 
~-catenin is required for postnatal bone maintenance in mice since an osteoblast-
specific ~-catenin mutation led to osteopenia and increased numbers of osteoclasts in 
mice (115). Releasing Wnt during degradation or remodeling of extracellular matrix 
might be the potential source of Wnt for bone formation microenvironment. In vitro 
studies indicate that osteoblasts may also produce Wnts. Wnt 7b is produced by 
osteoblasts (116). Wntl, Wnt4, and Wnt14 (but not Wnt3a) were also detected in 
calvarial tissue and ex vivo primary calvarial osteoblast cultures (117). Wntl, Wnt4, 
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Wnt5a, and Wnt7a were detected by RT-PCR in at least two of four osteosarcoma cell 
lines; but Wntll was not detected in any of these cells (118). BMP2 induced Wntl and 
Wnt3a expression in C3H10T½ cells (114) and thus may play a role in initiating 
autocrine Wnt signaling. ~-catenin signaling can also induce BMP2 function in new 
bone formation (119). 
Many studies focused on the role of ~-catenin in the osteoblast lineage (120-123). 
Studies suggest that during skeletal lineage differentiation, chondrogenesis might be the 
default state and that inhibition of chondrogenesis by a ~-catenin mediated Wnt-signal is 
required for differentiation of the other cell lineage. A more direct study showed that 
activation of ~-catenin by lithium treatment has potential to improve fracture healing, but 
only when utilized in later phases of repair, after mesenchymal cells have become 
committed to the osteoblast lineage (124). 
All of the studies indicated the crucial role of Wnt/~-catenin signaling pathway in 
extracellular matrix formation during the process of bone repair or formation, which will 
unavoidably involve LOX as well. 
Small interference RNA (siRNA) and micro RNA (miRNA) 
miRNA and siRNA are two types of small RNA molecules, having a central role 
m RNA silencing and interference. Several other types of small non-coding RNA 
molecules such as tiny non-coding RNA (tncRNA), small modulatory RNA (smRNA) 
and small nucleolar RNAs (snoRNAs) also have important cellular functions (125). Both 
siRNA and miRNA are involved in the same pathway by the processing of genome 
encoded RNA hairpins, which play a role in developmental regulation (126-129). The 
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present study focuses on elucidating the regulatory aspects of TNFa stimulated miRNAs 
on LOX mRNA expression in Wnt inducted C3Hl OT½ cells. 
siRNA was first discovered by David Baulcombe 's group as part of post-
transcriptional gene silencing in plants (130). Shortly after, synthetic siRNAs were 
shown to be able to induce RNA inference (RNAi) in mammalian cells by Thomas Tuschl 
group (131). siRNA is a class of double-stranded RNA molecules, 20-25 nucleotides in 
length, that play a variety of roles in biology. Their structure is the result of processing 
by Dicer, an enzyme that converts either long dsRNAs or small hairpin RNAs into 
siRNAs (132). The most notable role of siRNA is its involvement in the RNA 
interference (RNAi) pathway, where it interferes with the expression of a specific gene. 
In addition to its role in the RNAi pathway, siRNA also acts in an antiviral mechanism or 
in shaping the chromatin structure of a genome. The complexity of these pathways is 
only now being elucidated. 
miRNAs were characterized in the early 1990s but were not recognized as a 
distinct class of biologic regulators with conserved functions until the early 2000s. Since 
then, miRNA research has revealed multiple roles in negative regulation (transcript 
degradation and sequestering, translational suppression) and possible involvement in 
positive regulation (transcriptional and translational activation). 
miRNAs are single stranded RNAs of 18-24 nucleotides in length, generated 
from an endogenous transcript containing a local hairpin structure by the action of an 
RNase-III type enzyme Dicer. miRNAs are post-transcriptional regulators that bind to 
complementary sequences on target mRNAs by a pairing of 6-8 nucleotides and 
subsequent formation of RNA-induced silencing complex (RISC), resulting m 
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degradation of target mRNAs, gene silencing and translational repression (126, 133). 
siRNAs can be exogenously (artificially) introduced into cells by various 
transfection methods to bring about the specific knockdown of a gene of interest. In 
essence, any gene whose sequence is known can, thus, be targeted based on sequence 
complementarity with an appropriately tailored siRNA. Transfection of an exogenous 
siRNA can be problematic because the gene knockdown effect is only transient, in 
particular, in rapidly dividing cells. One way of overcoming this challenge is to modify 
the siRNA in such a way as to allow it to be expressed by an appropriate vector, e.g., a 
plasmid. This is done by the introduction of a loop between the two strands, thus 
producing a single transcript, which can be processed into a functional siRNA. It is 
assumed (although not known for certain) that the resulting siRNA transcript is then 
processed by Dicer. 
miRNA Mimics are chemically synthesized, double-stranded RNAs which mimic 
mature endogenous miRNAs after transfection into cells. Transfection with "miRNA 
Mimics" can act like endogenous mature miRNAs and can elicit downstream gene 
expression or phenotypic changes. This technique permits elucidation of the targets and 
roles of particular miRNAs. These experiments enable study of the biological effects of 
mis-regulation of individual miRNA as well as confirmation of specific genes as targets 
of individual miRNA. Reduced gene expression after transfection of mimics provides 
evidence that the miRNA under study is involved in regulation of a particular gene. 
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Network of miRNA regulated gene expression: mRNA dagradation 
MicroRNAs (miRNAs) are key regulators of gene expression that have important 
roles in a wide range of biological processes, from differentiation and proliferation, 
apoptosis and metabolism (133-136). Compared with earlier studies that elucidated the 
regulation of miRNA at transcriptional level, recently, more and more studies 
substantially showed that mRNA degradation provides a major contribution to silencing 
(137-139). Besides, each miRNA targets hundreds of genes suggesting that a remarkably 
large proportion of the transcriptome is subject to miRNA regulation (133, 136), and that 
the majority of protein-coding genes are miRNA targets (138-141). 
Some recent publications emphasize mRNA degradation as an important aspect of 
miRNA-mediated repression of gene expression (137-139, 142-149). miRNA exerts its 
degradation on target mRNA by binding to part of the target mRNA sequence, which 
leads to endonucleolytic cleavage of the mRNA at the site of complementarity (150). 
However, for the vast majority of targets, cleavage may not be entirely abrogated by a 
very limited number of mismatches , depending on their position, that have a similar near-
perfect complementarity to their target sites can also promote degradation (150). In this 
case, miRNAs direct their targets to the cellular 5' to 3' mRNA decay pathway (143-149), 
where mRNAs are first deadenylated and then decapped. 
12 
Hypothesis 
Abnormalities of LOX expression and activity will result in multi-system 
disorders. Our previous study showed that LOX is down-regulated by TNFa in 
osteoblasts and this contributes to diminished collagen deposition and cross-linking 
(151). AGE up-regulates TNF-a in osteoblasts. (152) In our present study, we employed 
TNFa, as it is significantly increased in diabetes, to investigate Wnt regulated mRNA 
expression of LOX in the C3Hl OT½ cell line. We hypothesized that TNFa affects LOX 
mRNA expression at a post-transcriptional level via miRNA regulation. 
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Materials and Methods 
Cell culture and Wnt conditioned media preparation 
The Wnt producing cell line L Wnt 3A (Cat# CRL-2647) and parental control 
cells (Cat# CRL-2648) were purchased from ATCC. Cells were maintained in a-Minimal 
Essential Medium (a-MEM) with 10% FBS and antibiotics in a 37 °C humidified 
incubator supplement 5% CO2. Wnt 3A cells were also supplied with 0.4 mg/ml of 
0418. When they reached 75% ~ 90% confluence, cells were washed with Dulbecco's 
phosphate buffered saline (PBS) and then trypsinized with 0.25% trypsin/EDTA. Cells 
were collected in media containing 10% serum and counted. Thus cells were recovered 
by centrifugation at 800 ref, room temperature, and 8.5 x 106 cells were seeded into 150 
mm2 culture dishes. The next day culture dishes were changed with aMEM containing 
2% FBS and antibiotics, with or without 0418. Three days later, cultured media were 
collected and fresh collection media added to the dish. Media were again harvested after 
another four days. Media were pooled, filter sterilized, aliquoted in 200 ml and stored at 
4 ° C until used. 
TNFa treatment on C3H10T½ cell line after Wnt induction 
The C3Hl0T½ cell line was purchased from ATCC (Cat# CCL-226). Mouse 
TNFa (Cat# 315-0lA) was purchased from PeproTech. Cells were maintained and sub-
cultivated in aMEM with 10% FBS and antibiotics in a 37 °C humidified incubator 
supplement 5% CO2. Cells used for experiments were from passage 10 to passage 13. 
Cells were pre-treated with Wnt conditioned media and then treated with TNFa. Both 
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dose response and stability of LOX mRNA expression after Wnt induction m the 
presence or absence of TNFa were evaluated. 
Total RNA extraction 
Total RNA extraction was performed using RNeasy Mini Kit (Cat# 74106) from 
QIAGEN . Briefly, collected samples were moved into a QIAshredder spin columns 
placed in a 2 ml collection tube and centrifuged for 2 min at full speed. Then, 350 µl of 
70% ethanol was added to the homogenized lysate, and mixed. When completely mixed, 
600 µl of the sample was transferred to an RNeasy spin column placed in a 2 ml 
collection tube. After centrifuging for 15 seconds at 12,000 g, the flow-through was 
discarded. 700 µl RWI buffer was added to the same column and then centrifuged for 15 
seconds at 12,000 g. The column was washed twice by adding 500 µl buffer RPE to the 
same column and centrifuged. Finally, the spin column was moved to a new 2 ml tube 
and centrifuged to exclude ethanol before adding 30 ~ 50 µl RNase-free water to collect 
the RNA on the column membrane. After extraction and purification , RNA was stored at 
-80 °C. 
miRNA extraction 
Total RNA plus miRNA purification was performed by using miRNeasy Mini Kit 
(Cat# 217004) from QIAGEN. Briefly, 700 µl QIAzol Lysis Reagent was added to each 
60 mm cell culture dish. Cell lysates were collected with a rubber policeman , and then 
thoroughly mixed by adding 140 µl chloroform to homogenate. Cell lysates were 
15 
centrifuged for 15 minutes at 12,000 x g, 4 °C and the upper aqueous phase was 
transferred to a new collection tube and mixed with 1.5 volumes of 100% ethanol. The 
mixture was pipetted into an RNeasy mini spin column and followed the same protocol as 
general RN A extraction . 
Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
General mRNA RT-PCR 
TaqMan® Reverse Transcription Reagent (Cat# N8080234) was purchased from 
Applied Biosystems. Reverse transcription was performed by adding 3 µl 10 x RT 
buffer, 6.6 µl 5 x MgCh , 6 µl dNTP, 1.5 µl hexamers , 0.6 µl RNase inhibitor and 0.8 µl 
reverse transcriptase to each sample ranging from 0.5 µg to 4 µg per reaction. Mixed RT 
samples were put in a Bio-Rad thermal cycler for the following reaction: 25 °C for 10 
minutes, 37 °C for 60 minutes, 95 °C for 5 minutes and then on 4 °C. Samples were 
stored at -20 °C until PCR was performed. 
TaqMan® Gene Expression Assays, eukaryotic 18S (Cat# Hs03003631_gl) , 
TaqMan® Gene Expression Assays, LOX (Cat# Mm00495386_ml) , Mus ribonuclease 
III (Drosha) probe for real-time PCR (Cat# Mm01310009 _ml) and TaqMan® Universal 
PCR Master Mix (Cat# 4364338) were purchased from Applied Biosystem. For real-time 
PCR, each sample was mixed with 12.5 µl PCR master mix and 1.25 µl TaqMan probe 
running by Applied Biosystem 7300 system as following: 50 °C for 2 minutes, 95 °C for 
10 minutes , repeat cycle of 95 °C 15 seconds and 60 °C 1 minutes for 40 times. 
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miRNA RT-PCR 
miRNA RT was conducted with RT2 miRNA First Strand Kit (Cat# 331401) from 
QIAGEN. 1 µl miRNA primer, 2 µl RT buffer, 1 µl multiscribe RT enzyme and 1 µl 
nucleotides was added to each sample and put a in Bio-Rad thermal cycler for reaction as 
follows: 3 7 °C for 2 hours, 95 °C for 5 minutes and 4 °C after then. When miRNA RT 
was finished, 90 µl water was added and samples stored at -20 °C until PCR was 
performed. 
miRNA PCR was conducted by usmg QIAGEN RP SYBR Green qPCR 
Mastermix (Cat# 330520). Reactions were performed by mixing 12.5 µl SYBR Green 
Mastermix, 1 µl miRNA qPCR primer and 11.5 µl diluted sample. Reaction condition 
was the following: 95 °C for 10 minutes, repeat cycle of 95 °C 15 seconds, 60 °C 30 
seconds and 72 °C 30 seconds for 40 times. At the end of reaction, Applied Biosystem 
dissociation curve was run by default. 
miRNA PCR array 
Mouse miRNome RP Whole Genome miRNA PCR Array (QIAGEN MAM-
200A-2) was employed for screening regulated miRNAs. Total RNA including miRNA 
was extracted by a previously described method with extra caution. Highly concentrated 
total RNA was extracted and purified (260/280 above 2.0 and 260/230 above 1.7 is 
required; concentration at least 100 ng/µl). Four µg of total RNA was used for miRNA 
reverse transcription. After reverse transcription, 90 µl water was added to each sample. 
When PCR was performed, 10 µl of the sample was taken and diluted in 1175 µl of water 
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and 1275 µl of SYBR Green Mastermix. Totally 2550 µl ·of reaction reagent was 
prepared for each 96-well plate. Six plates for each sample, totally twelve plates, were 
performed with PCR to compare miRNA changes by samples with and without TNFa 
treatment after Wnt induction in C3Hl0T ½ cell line. 
Transfection with siRNA 
Mission Rnasen siRNA (Drosha) (Cat# EMU04671 l) and Mission control siRNA 
(Cat# SIC002) was purchased from Sigma. Syn~mmu-miR-203 miScript miRNA Mimic 
(Cat# MSY0000236) and AllStars Negative Control siRNA (Cat# 1027280) for miRNA 
were purchased from QIAGEN. 
Transfection by Lonza Amaxa 
Nucleofector ® Solution V, transfection cuvettes and Nucleofector® Device were 
purchased from Lonza. Cells used for transfection were subcultured in dishes for at least 
two days and reached 75% ~ 85% confluent. 
10 µl siRNA (200 pmol) of Drosha siRNA and control siRNA with 90 µl Amaxa 
buffer V was prepared to obtain 100 µl Amaxa buffer, respectively. Cells were 
trypsinized and 1 x 106 cells were suspend in 100 µl Amaxa transfection buffer with total 
amount of 200 pmol siRNA. Mixtures were placed in a plastic cuvette and set in the 
cuvette in holder. After running A-020 protocol on the Nucleofector ® Device, pre-
warmed whole media was added to pooled and re-suspended cells in each group. Finally 
cells were seeded in 6-well plates at the concentration of 7 .5 x 105 cells/well. 
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Transfection by QIAGEN HiPerfect 
HiPerfect Transfection Reagent (Cat# 30705) was purchased from QIAGEN . 
Cells used for transfection were subcultured in dishes for at least two days and reached 
75% ~ 85% confluent. 
Total cell numbers and culture media volume were calculated before the 
transfection with the concentration of 7 .5 x 105 cells/well in 6-well plates. The total 
volume of siRNA (final concentration as 5 nM) and HiPerfect Transfect Reagent (6 µ1/ml 
in final volume) needed for the transfection was calculated and diluted in four times of 
no-antibiotics FBS free culture media. HiPerfect Transfection Reagent was added and 
incubated at room temperature for 5 to 10 minutes to allow the formation of transfection 
complexes. Cells were added into the mixture and the mixture was diluted with no-
antibiotics 10% serum culture media to the final volume needed to seed in 6-well plates. 
Cells were cultured at 3 7 °C, 5% CO2 for at least 18 hours to recover before serum 
starvation. 
Western Blotting 
Samples for Western Blotting were prepared by adding lysis buffer (25 
mM Tris•HCl , pH 7.6, 150 mM NaCl , 1% NP-40 , 1% sodium deoxycholate , 0.1% 
sodium dodecyl sulfate (SDS)) to each culture well. Samples were mixed with sample 
buffer supplemented with ~-mercaptoethanol ( 40µ1/ml) and boiled for 5 minutes. 
After quantification and calculation , equal amounts of samples were loaded on 
SDS-PAGE (denaturing polyacrylamide gel electrophoresis) and then transferred to a 
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PVDF membrane. The membrane was treated with 5% milk for 2 hours to block non-
specific binding and then washed 5 times, 5 min each with TBS with shaking. The 
membrane was labeled by cutting comers , and was incubated with Drosha antibody (Cell 
Signaling 3410) mixed with either 5% milk or 5% w/v BSA, 1 x TBS, 0.1 % Tween-20 at 
4 °C overnight with gentle agitation, and washed 5 times, 5 min each with TBS with 
shaking. Then the membranes were incubated in diluted goat-anti-rabbit lgG ( diluted 
1 :2000 in either 5% milk or 5% w/v BSA, 1 x TBS, 0.1 % Tween-20) for 1 hour with 
gentle agitation. Finally, the membranes were washed in PBS 5 times, 5 min each with 
gentle agitation. Bands were visualized with Immobilon Western Chemiluminescent 
HRP Substrate (ECL) (Millipore Cat# WBKL SO 100) Western Blotting detection 
reagent. 
20 
Results 
mRNA expression of LOX by Wnt stimulation 
First, the effect of newly made Wnt3a conditioned culture media on C3Hl OT½ 
cells was tested to confirm that LOX mRNA levels would be up-regulated by Wnt3a 
conditioned media, as was reported earlier (153). Wnt conditioned media and control 
conditioned media were collected and filter sterilized as described in Materials and 
Methods. C3Hl OT½ cells were trypsinized into new dishes and allowed at least 5 hours 
to attach to the dish. After 18 ~ 22 hours of serum starvation, cells were treated with 
Wnt- or control conditioned media for an additional 18 ~ 20 hours to test the success of 
the conditioned media collection and sterilization (same experiment was repeated at least 
three times). After total RNA extraction, RT-PCR was performed to measure LOX 
mRNA expression levels as shown in Figure 1. Under Wnt3a stimulation, LOX mRNA 
expression increased about three times compared with the control group, which is 
consistent with the result of previous report (153). This provides a study model to 
investigate effects of TNFa on Wnt3a-stimulated LOX mRNA expression in our later 
experiments. 
21 
C 
0 
"in 
"' 
4 
f 3 
a. )C 
GI 
ct 
z 
a: 
E 2 
0 
~ 
..., 
C 
0 
u 
.s 1 
0 
~ 
n, 
a: 
0 
mRNA expression of LOX by Wnt induction 
** 
--i 
Control Wnt 
Figure 1 Real-time PCR analysis of LOX mRNA expression by Wnt stimulation. 
After 18 ~ 20 hours serum starvation , cells were treated with conditioned 
media collected and filter sterilized from L Wnt 3A cells and the parental 
cells as control. Compared to control conditioned media, Wnt3a conditioned 
media treated cells increased LOX mRNA expression by 3.2 fold (**: P < 
0.01). 
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Effect of TNFa on LOX mRNA stability 
When a high level of LOX mRNA expression is stably available, we conducted a 
series of experiments to evaluate the effect of TNFa on LOX mRNA stability. This 
experiment was carried out because data obtained in the laboratory indicated that TNF-a 
down-regulation of LOX under these conditions did not occur by a transcriptional 
mechanism. 
The dose response of TNFa on LOX mRNA stability was evaluated at 24 hours 
after treatment. Cells were seeded into 6-well plates at a density of 7 .5 x 105 cells per 
well. Each condition was prepared with triplicate wells. After cells attached to the 
culture well bottom, cells were exposed in aMEM with 0.4% FBS and antibiotics for 
serum starvation for 18 ~ 24 hours. At the end of serum starvation, Wnt conditioned · 
media was diluted 5-fold to obtain the same serum concentration as serum starvation 
(0.4%). Diluted Wnt3a conditioned media and Control conditioned media were added to 
each well and cells were cultured for an additional 18 - 20 hours. Media were then 
changed to Wnt/Control conditioned media supplemented with 0, 10, 20, 40, 70 and 100 
ng/ml TNFa for 24 hours. At the end of treatment , 350µ1 RLT buffer (enclosed in 
RNeasy Mini Kit, Cat# 74106) containing with 3.5 µI P-mercaptoethanol was added in 
each 6-well-plate well. After total RNA extraction, RT-PCR was performed to evaluate 
the effect of TNFa on LOX mRNA levels (Fig. 2). LOX mRNA levels had a sharp 
decrease from 20 ng/ml and did not vary much by increasing the concentration of TNF a 
more than 20 ng/ml. Therefore, 20 ng/ml of TNF a would be the optimal for following 
studies . 
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Figure 2 Dose response of TNFa on LOX mRNA expression at 24 hours. Data were 
obtained by calculating the ratio relative to the control (0 ng/ml TNF-a) LOX 
mRNA expression. Both TNFa treated and control groups were pre-treated 
with Wnt conditioned media. LOX mRNA expression was lower in the 20 
ng/ml TNF a treatment group. 
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According to the result of dose response, the experimental design to determine the 
effect of TNFa on the stability of LOX mRNA in Wnt3a treated cells as a function of 
time is shown in Figure 3. 
After serum starvation, cells were treated with Wnt3a conditioned media for 18 
to 24 hours. At the end of Wnt3a pre-treatment , 20 ng/ml TNFa was added and cultured 
for an additional 4 hours. Then culture media were replaced with new Wnt conditioned 
media supplemented with or without TNFa and a transcription inhibitor, 5, ~ 
dichlorobenz-imidazole riboside (DRB). Meanwhile, the time O sample was collected as 
a control by adding 350 µl RLT buffer (enclosed in RNeasy Mini Kit, Cat# 74106) 
containing 3 .5 µl P-mercaptoethanol. The remaining samples were collected at intervals 
(2, 4, 8, 12 and 24 hours). At each time point triplicate wells were collected. LOX 
mRNA levels were determined by qPCR after RNA extraction. 
PCR result was exported to GraphPad Prism Version 5.02 for Windows. A trend 
line was generated in a log scaled graph to show the different tendency between the 
Control and TNFa treated group line (Figure 3). The formula of the trend line for control 
group is y = -0.023 lx + 1.068 (R2 = 0.5111); the formula of the trend line for TNFa 
treated group is y = -0.0301x + 0.999 (R2 = 0.7891). As shown in Fig. 4, LOX mRNA 
expression decreased faster in TNF a treated group compared to the untreated group. 
Therefore , treatment by TNFa of Wnt3a-treated C3Hl OT½ cells reduces LOX mRNA 
levels by a post-transcriptional mechanism. 
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Figure 3 After attaching to .the bottom of culture wells, cells were put in culture media 
with 0.4% FBS. After 18 ~ 24 hours' serum starvation, Wnt3a conditioned 
media was diluted 5 times to obtain 0.4% FBS culture media and added to 
cells for an additional 18 hours. Four hours before collecting control sample 
(time 0), TNFa was added in each well in 6-well plate. Control samples 
were collected by adding 350 µl RNeasy Mini Kit lysis buffer supplemented 
with 3.5 µI ~-mercaptoethanol, media in other wells were changed to Wnt +/-
TNFa supplemented with 20 µg/ml DRB. Cell samples were collected at the 
end of 2, 4, 6, 8, 12 and 24 hours. 
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Figure 4 Effect of TNFa on LOX mRNA stability in Wnt3a-treated C3Hl OT½ cells. 
Linear trend line of non-TNFa treated and TNFa treated group was 
developed in Software Graphics . in log scale. All samples were pre-treated 
with Wnt conditioned media. Both TNFa treated and non-treated groups 
were pre-treated with Wnt conditioned media. LOX mRNA expression 
showed lower level in TNFa treated group compare with non-treated group. 
The same experiment was repeated at least three times and similar tendency 
was obtained. A typical graph is presented. 
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Silencing of Drosha by siRNA 
Based on the previous data, we hypothesize that the effect of TNFa on LOX 
mRNA is at the post-transcriptional level and this mRNA degradation of LOX mRNA is 
through miRNA regulation. Since Drosha is the initial step to process miRNA, we chose 
silencing Drosha to deplete miRNA to reverse the reduction effect of TNFa on LOX 
mRNA expression. Efficiency of Drosha silencing would be examined by detecting 
Drosha by Western Blotting. 
Determine optimal Drosha antibody conditions 
Firstly, the optimal condition of Drosha antibody was determined. 
Two lots of Drosha antibody (A and B) was purchased from Cell Signaling. 
Different conditions were tested with equal amount of positive control 293 cell line 
extract, which is included in the manual. Primary or secondary antibodies were mixed in 
milk or BSA and tested on SDS-PAGE, respectively. The same experiment was repeated 
once and the typical image is shown in Figure 5. Target bands could be barely seen when 
antibody was mixed with milk contained in the blocking solution. Both target bands are 
visible in the BSA protocol. However, Drosha is expressed at very low levels in C3Hl OT 
½ cells compared with the positive control 293 cells. 
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Figure 5 Drosha antibody Western blot under different conditions. Two lots of 
antibodies were purchased from Cell Signaling labeled A and B. Antibodies 
were mixed with milk or BSA to optimize conditions. PVDF membrane was 
visualized by spraying ECL Western Blotting reagent. Film was exposed 3 
minutes to the membrane before development. Drosha bands from C3Hl0T ½ 
cells were completely invisible in milk mixed and treated sample; when 
antibody mixed and treated with BSA, Drosha bands became detectable but 
much less than it in positive control 293 cells. 
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Evaluation of Drosha silencing efficiency by Western Blotting 
When optimal Western Blotting conditions were determined and antibody 
specificity was confirmed, an experiment was designed to evaluate the efficiency of 
Drosha silencing by TNFa. 
The treatment protocol after transfection is shown in Figure 6. After Drosha 
siRNA transfection, cells were left for 18 ~ 20 hours to recover, serum starvation was 
started for an additonal 18 ~ 20 hours. At the end of serum starvation, cells were pre-
treated with Wnt conditioned media. After 18 ~ 20 hours, TNFa was added to the cell for 
another 18 ~ 20 hours. Samples were collected at the end of culture and Western Blotting 
was performed to detect Drosha. 
Transfection 
18 ~ 24 h 
serum starvation 
18 ~ 24 h 
Wnt pre-treatment 
18 ~ 24 h 
Wnt/TNFa 
treatment l 18 ~ 24 h Cell recovery ____ __,, -----,,..---- ~----.. ___ _,, ________ _,, ___  
r l l 
Serum free treatment Wnt Treatment of TN Fa 
Figure 6 Treatment protocol to evaluate effect of TNFa on miRNA or LOX mRNA 
expression in Drosha transfected C3 H 1 OT½ cell line. After transfection, leave 
cells for at least 18 hours to recover. Cells were then treated with serum free 
culture media (0.4% FBS) for another 18 ~ 24 hours. At the end of serum 
starvation, cells were treated with Wnt condition media for 18 ~ 24 hours 
before adding TNFa (20 ng/ml) to the Wnt condition media. TNFa 
treatment was stopped 18 ~ 24 hours later by adding lysis buffer into each 
well. 
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Two different transfection methods, Amaxa from Lonza and HiPerfect from 
QIAGEN, were conducted to silence Drosha. After treatments , samples were collected 
by adding lysis buffer into triplicate wells. Western Blotting was employed to estimate 
the efficiency of Drosha silencing. 
SDS-PAGE was run along with positive control 293 cell extracts. None of the 
experimental samples from either transfection method is visible on the exposed film, but 
the positive control is well developed under the same condition (Figure 7). Each 
transfection method was repeated 3 times and none of the samples is visible. Therefore, 
evaluation of the efficiency of Drosha silencing could not be accomplished by Western 
Blotting. 
1 2 3 4 5 6 marker 293 
Amaxa 
Hi Perfect 
Figure 7 Evaluation of Drosha silencing efficiency. siRNA transfection was 
conducted by both Amaxa and HiPerfect method. Samples were collected by 
adding SDS PAGE sample buffer to process Western Blotting. At the end of 
Western Blotting, PVDF membrane was visualized by spraying ECL Western 
Blotting reagent. 'Film was exposed 4 minutes to the membrane before 
development. 1 ~ 3 are Control siRNA triplicates ; 4 ~ 6 are Drosha siRNA 
triplicates. Marker labeled as 122 kDa. 
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miRNA array screening 
Since we failed to monitor the efficiency of silencing Drosha to block the 
formation of miRNA, we changed the strategy to screen the whole mouse miRNA by 
conducting a miRNA PCR array system offered by QIAGEN to find out the specific 
miRNA involved in the TNFa induced degradation of LOX mRNA expression. 
The RT2 miRNA PCR Array is designed to analyze miRNA expression using real-
time, reverse transcription PCR, or qRT-PCR, the most sensitive and reliable method for 
nucleic• acid expression analysis currently available. The arrays take advantage of a 
SYBR® Green real-time PCR detection system designed for high performance to analyze 
the expression of known mature miRNA sequences simultaneously. The mouse 
Genome V2.0 RT2 miRNA PCR Arrays contain 440 miRNA sequences as annotated by 
the Sanger miRBase Release 14. Each 96-well array plate contains a panel of primer sets 
for a thoroughly researched set of 88 miRNAs, plus four housekeeping assays and two 
RNA and PCR quality controls. To complete the miRNA PCR Array procedure, 
experimental small RNA samples are reverse transcribed into first strand cDNA, the 
template for the PCR, using the RT2 miRNA First Strand Kit. Then, the template is 
mixed with one of the specific and ready-to-use RT2 SYBR Green qPCR Master mixes. 
After then, aliquot the template mixture into each well of the same plate containing the 
pre-dispensed miRNA-specific assays. Real time PCR is performed to finally determine 
relative expression with real-time instrument and the ~~Ct method. 
Cell culture followed the protocol shown in Fig. 6. In order to meet the high 
quantity of total RNA needed to perform miRNA reverse transcription, 100mm dishes 
were utilized to culture and collect total RNA. Extra dishes were set aside checking for 
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the effect of Wnt treatment. At the end of culture 1.5 ml QIAzol Lysis Reagent, enclosed 
in miRNeasy Mini Kit, was added to the 100 mm dish. After RNA extraction, 
concentration was quantified. Both A260/A280 and A260/A230 in both TNFa treated 
and untreated samples were over 2.0. The concentrations in both samples were over 1300 
ng/µl. Before miRNA array was run, mRNA levels determined by qPCR indicated 
successful induction of LOX mRNA expression after the initial treatment of C3Hl OT½ 
cells with Wnt conditioned media (Fig. 8). 
miRNA reverse transcription was conducted following the Qiagen RT2 miRNA. 
First Strand Kit manual. 90 µl water was added to each sample after reverse transcription 
as recommended in manual. Then, each sample containing reverse-transcribed templates 
from INF a and control treated cells was aliquoted into 6 tubes, each for subsequent 
application to one 96-well miRNA primer pre-coated PCR plates for each sample, and 
frozen at -20 °C until used. Then one tube was thawed and mixed with SYBER green to 
perform each miRNA PCR 96-well plate as described in Methods. This was performed 
for each 96-well plate, containing primers for different miRNA targets. 
Upon the completion of PCR for the total of 12 plates (6 for non-TNFa treated 
control and 6 for TNFa treated sample), Excel-based PCR Array Data Analysis Template 
from the QIAGEN website was downloaded and utilized for the analysis of the miRNA 
PCR result. 
QIAGEN recommended four household control miRNAs: Snord 85, Snord 68, 
Snord 66 and Rnu6. Since the amount of miRNA Snord 85 expression is not consistent 
in TNFa treated and non-treated samples, three out of four recommended internal control 
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miRNAs were picked and set as household control miRNAs to calculate the change 
between TNFa treated and non-treated samples. Among the total of 528 tested miRNAs, 
the expression of 39 miRNAs was changed more than 4-fold in TNFa treated sample 
compared with TNFa non-treated control sample. The expression of 29 miRNAs was 
down regulated in TNFa treated sample compare with non-treated sample; 10 miRNAs 
were up regulated in TNFa treated sample compare with non-treated sample (Table). As 
shown in Fig. 9, a 3D profile and scatter plot was automatically generated by the 
software. 
Based on miRDB (http://mirdb.org/miRDBD, online database for miRNA target 
prediction and functional annotations in animals, we find a list of predicted miRNA 
related to LOX expression. By crossing check with the LOX expression related miRNA 
list, miR-203 is mostly up-regulated after TNFa treatment in out miRNA screen. 
Therefore, we decide to focus on miR-203 as our next step to further explore the 
mechanism ofTNFa related LOX mRNA degradation , since it was the most and only up-
regulated miRNA related to LOX expression. 
Even though miR-146a is not related to LOX expression, since it is the most 
dramatically changed miRNA in our pilot screen, we also monitored its change during the 
following experiments. 
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Figure 8 LOX mRNA expression check for miRNA array. Compared to control 
conditioned media treated cells, LOX mRNA expression level in Wnt 
conditioned media treated cells increased by 2.2 fold(**: P < 0.01 n=3). 
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Table 
Mature ID Fold Regulation RT2 Catalog 
miR-377 -34.3761 MPM00685A 
miR-33 -33 .4361 MPM00654A 
miR-301b -22.6798 MPM00633A 
miR-301a -21.0148 MPM00632A 
miR-219 -16.8733 MPM00597A 
miR-32 -16.5642 MPM00644A 
miR-3769 -13.0261 MPM01491A 
miR-708* -8.594 MPM01545A 
miR-141 -7.7812 MPM01407A 
miR-142-30 -7 .6211 MPM01408A 
mifl-19a* -6.6192 MPM00571A 
miR-297b-5p -6.379 MPM00623A 
rniR~4§6d:-5P -6.3496 MPM00722A 
....... .. ... .. . ..... 
miR-19a -5.9794 MPM01430A 
rniR~34b~~P -5 .9244 MPM00669A 
miR-29b -5.8563 MPM00629A 
miR-295 -5.3889 MPM01454A 
miR-19b -5.278 MPM00572A 
rniR-186* -5 .11 MPM01422A 
miR-l0la -4.9588 MPM01389A 
miR-450b-5p -4.936 MPM00709A 
rniR-450a-3p -4.8906 MPM01505A 
rniR-679 -4.8906 MPM00794A 
miR-16* -4.8344 MPM01417A 
miR-188-5p -4.7678 MPMO0SSSA 
miR-30e -4 .5948 MPM00642A 
miR-193 -4.357 MPM01426A 
miR-412 -4.357 MPM00696A 
miR-335-3p -4.3269 MPM01479A 
miR-196a * 4.1892 MPM01427A 
miR-1938 4.5211 MPMOl92lA 
miR-1190 4.9474 MPM01877A 
miR-450b-3p 5.2054 MPM01506A 
rniR-202-30 5.7624 MPM01434A 
rniR-208a 11.2096 MPM00583A 
miR-203 13.147 MPM01435A 
miR-155 13 .1775 MPM00540A 
miR-146a 47.5048 MPM00529A 
miR-1187 946.6365 MPM01867A 
Mouse miRNome RP Whole Genome miRNA PCR Array. miRNA changes 
more than 4-folds in TNFa treated samples compare with control were listed. 
Each individual miRNA primer is commercially available by QIAGEN with 
RT2 catalog number in the right column. 
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Mouse miRNome RT2 Whole Genome miRNA PCR Array. A: 3D graph of 
miRNA changes in TNFa treated sample compared with non-treated 
samples . B: scatter plot of miRNA in TNFa treated samples compared to 
non-treated samples. Changes more than 4-fold were defined outside of the 
double lines. 
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Evaluation ofTNFa on LOX mRNA expression in miR-203 mimic transfected cells 
miR-203 is the most up-regulated miRNA, which is predicted to be related to 
LOX in the whole mouse miRNA array. We, therefore, decided to transfect the miR-203 
mimic to C3Hl0T ½ cells to further explore its actual ability to target LOX mRNA 
expression. Since miR-146a is dramatically changed and previously well studied, we 
also monitored its change during the following experiments. 
The experimental design is same as that described in miRNA array screening 
shown in Fig. 6 except the culture dish size was changed from 150 mm dish to 60 mm 
and untransfected dishes were set along with miR-203 mimic and control transfections. 
At the end of culture, 0.7 ml QIAzol Lysis Reagent, enclosed in miRNeasy Mini Kit, was 
added to the 60 mm dish. miRNeasy Mini Kit was employed to extract total RNA 
including miRNA. miR-203 RT-PCR and LOX mRNA RT-PCR were performed, 
respectively. 
miR-203 mimic transfection after Wnt pre-treatment was checked by real-time 
PCR as shown in Fig. 10. miR-203 expression is dramatically high in transfected cells 
fed with both Control conditioned media and Wnt conditioned media. Even though the 
levels of miR-203 are different, the level of miR-203 in mimic transfected cells still 
expressed almost 80,000 fold more than in untransfected and control transfected cells 
without TNFa treatment four days after transfection (Fig. llA). This indicates, on a 
whole view, the transfection is successful and durable until the end of the experiment. 
The expression of miR-146a was not significantly changed in the TNFa untreated 
control group among untransfected , control transfected and miR-203 mimic transfected 
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cells. However, its expression was dramatically increased after TNF a treatment (Fig. 
llB). In untransfected cells, the level of miR-146a expression was increased to 30 folds 
after TNFa treatment. The miR-146a expression in miR-203 mimic transfected cells 
showed up to 144 folds ratio to untransfected TNFa untreated miR-146a expression 
level. 
By studying the LOX mRNA expression pattern after TNFa treatment in two sets 
of independent culture and treatment experiments, we can see that LOX mRNA 
expression is suppressed by TNFa treatment in both untransfected cells and scrambled 
control transfected cells, which confirmed the same pattern as previous data (Fig. 11 C). 
In the TNFa untreated group, LOX mRNA expression in miR-203 mimic transfected 
cells was reduced to 80% of untransfected and control transfected cells. Similar to the 
suppression of LOX mRNA expression in TNFa treated untransfected cells, LOX mRNA 
level in control transfected and miR-203 mimic transfected cells were about half of the 
level in TNF a untreated groups. However, no significant differences were detected 
among the untransfected, control transfected and mimic transfected cells in the TNF a 
treated group. 
In summary, this set of experiments showed that the miR-203 regulation and LOX 
mRNA regulations are consistent with the hypothesis that the effect of TNFa on LOX 
mRNA expression in Wnt3a treated C3Hl OT½ cells is very possibly through miRNA 
regulation. 
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Figure 10 rniR-203 expression in miR-203 mimic transfected C3Hl OT½ cells. Samples 
were collected after Wnt pre-treatment. Compared with untransfected and 
control transfected cells, miR-203 expression is at least 80,000 times higher 
in all rniR-203 mimic transfected groups, which confirmed the effect of miR-
203 mimic transfection durability at the end of the culture. 
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Figure 11 miR-203 , miR-146a and LOX mRNA expression after TNFa treatment. All 
samples are pre-treated with Wnt conditioned media for at least 18 hours. 
miR-203 , miR-l 46a and LOX mRNA showed significant differences in miR-
203 mimic transfected cells after TNF a treatment compare with other groups 
as labeled in A and C. (A) miR-203 expression in miR-203 mimic 
transfected cells is very high in both TNF a treated and untreated groups , as 
expected. (B) miR-146a expression increased 30 times after TNFa treatment 
in untransfected cells. In miR-203 mimic transfected cells , miR-146a 
showed even higher expression level. In the TNF a treated group, miR- l 46a 
showed more than a 3-fold increase in miR-203 mimic transfected cells 
compared with untransfected cells. (C) LOX mRNA expression was 
significantly lowered in miR-203 mimic transfection sample in the absence 
of TNF-a. LOX mRNA expression in untransfected, control transfected and 
mimic transfected cells after TNFa treatment showed roughly one-third to 
half the level of reduction compared to TNFa untreated cells. Two 
independent culture samples were collected and each assayed in triplicate 
with real-time PCR. T-test was performed to compare significance between 
different samples (n=6). * *: p<0.0 1; *: P<0.05 
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Discussion 
Wnt increased LOX in C3H10T½ cells 
LOX is synthesized as a 50 kDa precursor and increased cell layer associated pro-
LOX has been found to correlate well with increased synthesis of LOX in developing 
osteoblasts (71 ). Our finding is consistent with a previous study of increased LOX 
mRNA expression by the stimulation ofWnt in the C3H10T½ cell line (153). 
Role of TNFa in diabetes In present study, we evaluated the effect of TNFa on LOX 
mRNA expression in Wnt3a induced C3H10T½ cells by both dose response and mRNA 
stability (Fig. 4). LOX mRNA stability experiments determined as a function of time 
after blocked transcription showed that TNFa suppressed LOX mRNA stability. 
Therefore, the down regulation by TNFa on LOX mRNA is exerted by increased mRNA 
degradation after transcription. According to the significant role of TNFa in diabetes 
and the critical effect of LOX in extracellular matrix formation, we can also hypothesize 
that the weak bone formation, osteopenia, low bone density or less deposition of bone 
might be because of down regulated LOX in the presence of high levels of TNFa in 
diabetes patients. 
The down regulation of LOX mRNA by TNFa is through miRNA regulation 
Since miRNA regulation of mRNA stability is a major mechanism of post-
transcriptional regulation, we extended our study to explore the mechanism of this down 
regulation of LOX mRNA by TNFa treatment based on miRNA. We screened the whole 
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miRNome in mice to find out the effect of TNFa using a QIAGEN Mouse miRNome 
RP Whole Genome miRNA PCR Array. 
Mouse miRNome RT2 Whole Genome miRNA PCR Array 
In order to find out the exact miRNA that might be related to LOX mRNA 
degradation under the effect of TNFa treatment , we did the whole miRNome screening 
by QIAGEN Mouse miRNome RP Whole Genome miRNA PCR Array. 
As discussed previously, miRNA is a network regulation: a single miRNA will 
target multiple of genes; and a single gene or protein will involve many miRNA 
regulations. In present study, we found 39 out of totally 528 miRNAs were changed after 
TNFa treatment in Wnt induced C3H10T ½ cells. Two thirds of them are down 
regulated , which means the miRNA gene itself was suppressed; one third of them are up 
regulated. 
Significantly, miR-1187 is dramatically increased over 900 folds in the TNFa 
treated sample compare with TNFa untreated sample. Even though mmu-miR-1187 was 
identified along with mmu-miR-574-5P and mmu-miR-466f-3P in mouse first intron of 
procollagen type III alpha 1, its function is still unclear (miRBase Sequence Database). 
Another highly up regulated miRNA is miR-146a. In the PCR assay, it changed 
47.5 folds in TNFa treated sample. miR-146a is involved in haemopoiesis (154), 
inflammatory cells (155, 156), both innate immune response (157, 158) and virus 
infection (159, 160). Interestingly, Nakasa et al. (161) have reported that TNFa induced 
miR-146a expression in human rheumatoid arthritis synovial fibroblasts , which support 
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our finding in present study. Active studies on focusing on cancers also showed miR-
146a involvement. Aberrant expression of miR-146a might be linked to the development 
of cancerous phenotypes (162, 163). Indeed, this content~on is supported by reports of 
elevated miR-146a levels in papillary thyroid carcinoma ( 164-166), cervical cancer ( 167), 
breast cancer and pancreatic cancer ( 168), whereas reduced miR-146a expression is 
associated with prostate cancer ( 168, 169). In addition, miR-146a can suppress the 
metastatic ability of breast cancer cells partially through decreasing constitutive NF-Kl3 
activity (170), whose activation can promote the survival and metastatic potential of 
cancer cells (171 ). It is reported that breast cancer metastasis suppressor 1, which is a 
nuclear protein that can suppress the metastasis of numerous cancer cells, increases miR-
146a expression in metastatic breast cancer cells. On the contrary, miR-146a 
transduction · down-regulates expression of epidermal growth factor receptor, inhibits 
invasion, migration and metastatic ability of metastasis MDA-MB-231 cells (172), which 
indicated a therapeutic potential to suppress cancer metastases. Recently evidence also 
showed that miR- l 46a is involved in extracellular matrix protein production. Feng et al 
showed a novel, glucose-induced molecular mechanism in which miR-146a participates 
in the transcriptional circuitry regulating extracellular matrix protein production in 
diabetes (173). Panguluri et al stated a possibility of skeletal muscle loss through miR-
146a (174). Another interesting study also demonstrated the active role of miR-146a in 
cartilage regeneration by regulating several extracellular matrix enzymes (175). 
However, so far there is no report that directly links miR-146a and LOX. Specific qPCR 
assays of miR-146a expression levels in miR-146 mimic-transfected cells experiment 
(Fig. 10) confirmed the miRNA PCR array result (Table) and our repeated data is 
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consistent with previous report (161). Interestingly, the miR-146a expression level is 
much higher in TNFa treatment compared with TNFa untreated cells. Furthermore, in 
TNF a treated group, miR-146a expression is three to four times higher in miR-203 
mimic transfected cells than that in untransfected and control transfected cells (Fig. 10). 
This might indicate a synergistic effect of miR-203 and TNFa on miR-146a expression. 
Many other miRNAs were significantly changed as well. miR-33 regulates 
cholesterol efflux and HDL biogenesis (176-178); miR-301 might be involved in 
different origin carcinomas , such as breast cancer (179), lung cancer (180), hepatocellular 
carcinomas (181 )and pancreatic cancer (182). In present study, we focus only on 
possible LOX related miRNAs. Therefore, we picked up miR-203, which is predicted as 
LOX related miRNA according to miRDB database, and miR-146a , which is significantly 
increased in TNFa treated sample as well. 
miR-203 mimic transfection 
miR-203 is generally recognized as a tumor suppressor microRNA often silenced 
m different malignancies (183-190). miR-203 is also involved in a key molecule 
controlling the p63-dependent proliferative potential of epithelial precursor cells both 
during keratinocyte differentiation and in epithelial development by regulating the 
DeltaNp63 expression level (191, 192). Other reports indicated miR-203 is involved in 
skin morphogenesis (193), since up regulation of miR-203 in human keratinocytes is 
required for their differentiation (194). High level of miR-203 was reported to inhibit 
human papilloma virus (HPV) amplification and that HPV proteins act to suppress 
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expression of this miRNA to allow productive replication in differentiating cells (194). 
Later, it was reported that expression of miR-203 is dependent on p53, which may 
explain the expression of HPV type 16 can disrupt the balance between proliferation and 
differentiation , as well as the response to DNA damage, in keratinocytes (195). 
miR-203 mimic transfection as a method was applied to the study of esophageal 
squamous cell carcinoma (192). In that study, it was found that miR-203 mimic siRNA 
signicantly inhibited cell proliferation in esophageal squamous cell carcinoma meanwhile 
miR-203 could down-regulate endogenous LiNp63 expression , which is an important 
oncogene regulating cell proliferation in some tumors, at the post transcriptional level. 
However, re-expression of LiNp63 in cells transfected with miR-203 mimic significantly 
attenuated the miR-203 induced inhibition of cell proliferation. 
From previous data in our study, we highly suspected the down regulation of LOX 
mRNA expression after TNFa treatment occurs at the post transcriptional level. The 
miRNA screen offered us the opportunity to identify the exact miRNAs involved in this 
process. By cross-referencing a predicted miRNA target list in an online database 
(miRDB) to target LOX, we chose miR-203 as our next step to focus on. We also 
introduced the miR-203 mimic into the cells and compared the change with TNFa 
treatment with untransfected and control transfected cells. After 72 hours' serum-free 
culture with several media changes, the miR-203 level is still significantly high in miR-
203 transfected cells (Fig. 10). The significantly lower LOX expression level in TNFa 
untreated Wnt-stimulated miR-203 mimic transfected cells may result from miR-203 
mimic suppressing as we expected, even though the effect was less than expected. LOX 
mRNA expression after TNFa treatment showed roughly half of the level compare with it 
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in TNF a untreated cells, which showed the same pattern as previous experiments (Fig. 
3). However, the expression of LOX mRNA in miR-203 mimic transfected cells showed 
no significant difference compared with untransfected and control transfected cells after 
TNFa treatment. This might because TNFa stimulated miR-203 was sufficient to inhibit 
LOX mRNA expression. In the present study, a significantly higher level of LOX mRNA 
in miR-203 transfected cells without TNFa treatment occurred whereas we expected the 
same level as in miR-203 transfected TNFa treated cells. This could be due to a low 
transfection efficiency of mimic miR-203 into C3Hl OT½ cells. 
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Conclusion: 
TNFa down regulated LOX mRNA stability in Wnt induced C3HlOT½ cells in a 
dose and time dependent manner. miR-203 was up-regulated after TNFa treatment in 
Wnt induced C3HlOT½ cell line. TNFa also induced miR-146a expression in Wnt 
induced C3Hl OT½ cell line. miR-203 mimic transfected cells successfully suppressed 
LOX mRNA expression without TNFa treatment, even though it was not suppressed as 
much as expected due to possible insufficient transfection. miR-146a expression 
occurred at a significantly higher level than control cells after TNFa treatment in miR-
203 mimic transfected Wnt pre-treated cells. Therefore, it is very possible to speculate 
that LOX mRNA expression is regulated at the post transcriptional level by miRNA, 
specifically miR-203. 
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